The Effects of Pretreatment with Atorvastatin, Fenofibrate, or Both Drugs in a Mouse Model of Acute Lipemia Induced by the General Lipase Inhibitor Poloxamer 407
Authors:
- T. A. KorolenkoTKT. A. Korolenko
- T. P. JohnstonTJT. P. Johnston
- N. V. TamkovichNTN. V. Tamkovich
- V. A. VavilinVVV. A. Vavilin
- N. P. BgatovaNBN. P. Bgatova
- I. D. IvanovIII. D. Ivanov
- G. S. RusskikhGRG. S. Russkikh
- E. V. KoldyshevaEKE. V. Koldysheva
- E. C. KorolenkoEKE. C. Korolenko
- V. I. KapustinaVKV. I. Kapustina
- 1 September 2024
- journal article
- research article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
- Vol. 18 (3) , 214-230
Abstract
Dyslipidemia is a well-known risk factor for the development of cardiovascular diseases and atherosclerosis. The effects of combined pretreatment with atorvastatin and fenofibrate (Tricor) were studied in a mouse model of acute lipemia induced by a general lipase inhibitor, poloxamer 407 (P-407, 250 mg/kg). This lipemia is characterized by significantly increased serum levels of triglycerides (TG), low-density lipoprotein (LDL) cholesterol, together with decreased concentration of high-density lipoprotein (HDL) cholesterol. Atorvastatin pretreatment had a hypolipidemic effect, decreasing concentrations of LDL cholesterol and increasing HDL cholesterol. Pretreatment of mice with fenofibrate decreased TG level, increasing HDL cholesterol. Combined pretreatment with atorvastatin and fenofibrate decreased TG and total cholesterol. Elevation of the serum cystatin C level was found in control and lipemic mice pretreated with atorvastatin, fenofibrate, or both. Liver expression of lysosomal acid lipase increased in atorvastatin- or/and fenofibrate-pretreated groups of lipemic mice. It was concluded that increased expression of lysosomal acid lipase is related to the removal of lipid droplets from hepatocytes, thus preventing acute lipemia. Lastly, cystatin C may be a “theranostic” biomarker for hypolipidemic drugs.Keywords
This publication has 55 references indexed in Scilit:
- Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV StudyClinical Therapeutics, 2021
- Proteomics and metabolomics analyses reveal the full spectrum of inflammatory and lipid metabolic abnormalities in dyslipidemiaBiomedical Chromatography, 2021
- Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic DiseasesCurrent Atherosclerosis Reports, 2020
- Regulation of the human lipoprotein lipase gene by the forkhead box transcription factor FOXA2/HNF-3β in hepatic cellsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2017
- Lipases and their inhibitors in health and diseaseChemico-Biological Interactions, 2016
- Serum Creatinine Determined by Jaffe, Enzymatic Method, and Isotope Dilution‐Liquid Chromatography‐Mass Spectrometry in Patients Under HemodialysisJournal of Clinical Laboratory Analysis, 2012
- Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant TherapyThe American Journal of Cardiology, 2010
- Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group studyClinical Therapeutics, 2009
- Towards novel anti-cancer strategies based on cystatin functionCancer Letters, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001